Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response

Nat Commun. 2023 Feb 25;14(1):1078. doi: 10.1038/s41467-023-36826-0.

Abstract

Protein arginine methyltransferase (PRMT) 5 is over-expressed in a variety of cancers and the master transcription regulator E2F1 is an important methylation target. We have explored the role of PRMT5 and E2F1 in regulating the non-coding genome and report here a striking effect on long non-coding (lnc) RNA gene expression. Moreover, many MHC class I protein-associated peptides were derived from small open reading frames in the lncRNA genes. Pharmacological inhibition of PRMT5 or adjusting E2F1 levels qualitatively altered the repertoire of lncRNA-derived peptide antigens displayed by tumour cells. When presented to the immune system as either ex vivo-loaded dendritic cells or expressed from a viral vector, lncRNA-derived peptides drove a potent antigen-specific CD8 T lymphocyte response, which translated into a significant delay in tumour growth. Thus, lncRNA genes encode immunogenic peptides that can be deployed as a cancer vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes
  • Histocompatibility Antigens Class I / genetics
  • Histocompatibility Antigens Class I / metabolism
  • Humans
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • Peptides / genetics
  • Protein-Arginine N-Methyltransferases
  • RNA, Long Noncoding* / genetics

Substances

  • RNA, Long Noncoding
  • Histocompatibility Antigens Class I
  • Peptides
  • PRMT5 protein, human
  • Protein-Arginine N-Methyltransferases